The pharmaceutical industry faces an average of $1.3 billion in costs and 10+ years to bring a single drug to market, according to the Tufts Center for the Study of Drug Development. Throughout this journey, companies manage complex clinical trial data, maintain stringent regulatory compliance across multiple jurisdictions, and coordinate manufacturing processes where a single deviation can result in multi-million dollar recalls. Custom software has become essential infrastructure—not a luxury—for pharmaceutical companies navigating these operational challenges.
At FreedomDev.com, we've spent over 20 years building software solutions that address the specific technical challenges pharmaceutical companies face daily. Our work spans laboratory information management systems (LIMS) that track sample chains of custody, electronic batch record (EBR) systems that digitize manufacturing workflows, and serialization platforms that implement track-and-trace requirements for the Drug Supply Chain Security Act (DSCSA). We understand that pharmaceutical software isn't just about automation—it's about creating validated, auditable systems that satisfy FDA inspectors while improving operational efficiency.
Pharmaceutical companies operate in one of the most regulated industries globally, where software systems must comply with 21 CFR Part 11 requirements for electronic records and electronic signatures. This means every software solution must implement specific technical controls: secure, computer-generated time-stamped audit trails; authority checks to ensure only authorized individuals can use the system; operational system checks to enforce permitted sequencing of steps; and copy protection to ensure accurate and complete copies of records. These aren't optional features—they're fundamental requirements that must be baked into the software architecture from day one.
The pharmaceutical supply chain adds another layer of complexity. A typical drug product might involve active pharmaceutical ingredient (API) synthesis at one facility, formulation and fill-finish at a second location, packaging at a third site, and distribution through a network of wholesalers and specialty pharmacies. Each handoff requires precise documentation, temperature monitoring, and chain of custody tracking. Software systems must integrate data from manufacturing execution systems (MES), warehouse management systems (WMS), transportation management systems (TMS), and enterprise resource planning (ERP) platforms while maintaining data integrity across all touchpoints.
Clinical trial management represents another critical area where custom software delivers measurable value. Pharmaceutical companies conducting Phase II and III trials coordinate activities across dozens or hundreds of clinical sites, managing patient enrollment, electronic data capture (EDC), adverse event reporting, and regulatory submissions to institutional review boards (IRB). Off-the-shelf clinical trial management systems (CTMS) often require extensive customization to match specific protocol requirements, or they force companies to adapt their processes to software limitations. Purpose-built solutions integrate with existing EDC platforms like Medidata Rave or Oracle InForm while adding custom workflows for specific therapeutic areas.
Quality management in pharmaceutical manufacturing involves managing deviations, change controls, corrective and preventive actions (CAPA), and out-of-specification (OOS) investigations. Many companies still rely on paper-based systems or generic document management platforms that weren't designed for pharmaceutical workflows. These systems create bottlenecks during investigations, make trend analysis difficult, and complicate regulatory inspections. Custom quality management systems (QMS) implement pharmaceutical-specific workflows with built-in business rules that enforce procedural requirements, automatically route approvals to qualified personnel, and generate inspection-ready reports.
Serialization and track-and-trace requirements have transformed pharmaceutical packaging and distribution since the DSCSA took effect. Every saleable unit must carry a unique product identifier that includes the National Drug Code (NDC), serial number, lot number, and expiration date encoded in a 2D Data Matrix barcode. Manufacturers must capture and store this data, then transmit transaction information, transaction history, and transaction statements to trading partners. This requires integrating serialization systems with manufacturing lines, warehouse operations, and trading partner networks—a technical challenge that impacts both IT systems and operational processes.
Laboratory operations in pharmaceutical development involve managing complex analytical workflows, instrument data systems, and stability study protocols. Scientists use high-performance liquid chromatography (HPLC), mass spectrometry, dissolution testing, and other analytical methods to characterize drug substances and products. Each instrument generates data in proprietary formats that must be integrated into a laboratory information management system (LIMS), reviewed for compliance with validation protocols, and archived in a format that satisfies regulatory requirements for data integrity. Custom LIMS solutions connect disparate instruments, automate calculation procedures, and implement electronic signatures for all critical data reviews.
Our approach to pharmaceutical software development recognizes that technical excellence must be paired with regulatory understanding. We work alongside your quality assurance teams to develop validation strategies, create design specifications that map to user requirements, and execute installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) protocols. Our systems are designed to generate complete audit trails that capture the who, what, when, and why of every data change—not as an afterthought, but as a core architectural principle. With documented experience across multiple FDA-inspected facilities, we deliver software solutions that pass regulatory scrutiny while solving real operational problems.
The pharmaceutical industry continues to evolve with increasing adoption of continuous manufacturing, personalized medicine approaches, and decentralized clinical trials. These trends create new software requirements: real-time process analytical technology (PAT) data integration for continuous manufacturing, patient engagement platforms for direct-to-patient clinical trials, and advanced analytics for identifying optimal manufacturing parameters. Whether you're a contract development and manufacturing organization (CDMO) serving multiple clients, a specialty pharmaceutical company focused on orphan drugs, or an established manufacturer modernizing legacy systems, custom software provides the flexibility to address your specific operational requirements without forcing compromises that off-the-shelf systems demand.
We specialize in building custom software for your industry. Tell us what you're dealing with.
Pharmaceutical companies must ensure all electronic systems comply with FDA's 21 CFR Part 11 requirements for electronic records and electronic signatures. This regulation mandates specific technical controls including audit trails that capture original entries and all changes with timestamps and user identifications, validation protocols proving the system consistently produces expected results, and security controls preventing unauthorized access. Many commercial software packages claim 21 CFR Part 11 compliance but require extensive configuration and validation work to actually meet regulatory requirements. The technical challenge involves implementing compliant architecture while maintaining system usability—overly restrictive controls can make systems so cumbersome that employees seek workarounds, creating compliance risks that defeat the purpose of the regulations.
Pharmaceutical laboratories operate dozens of analytical instruments from different manufacturers, each producing data in proprietary formats: Agilent ChemStation for HPLC systems, Waters Empower for chromatography data, Thermo Scientific Chromeleon for ion chromatography, and specialized systems for dissolution, stability chambers, and spectroscopy. Scientists need unified access to this data for method development, validation studies, and batch release testing. However, integrating these instruments requires developing custom parsers for each data format, implementing middleware that captures raw data files, and ensuring that metadata (analyst ID, timestamps, audit trail entries) transfers intact to the central LIMS. The integration must preserve data integrity while making information accessible for analysis and regulatory inspections.
Clinical trials generate massive volumes of data from electronic data capture (EDC) systems, electronic patient-reported outcomes (ePRO) platforms, central labs, imaging core labs, and interactive response technology (IRT) systems managing randomization and drug supply. Study coordinators need integrated visibility across these disconnected systems to monitor patient enrollment, track protocol deviations, manage investigational product inventory, and identify data queries requiring resolution. Commercial CTMS platforms often require manual data entry or expensive custom integrations with each data source. The technical challenge involves building integration layers that pull data from multiple sources in near-real-time, reconcile patient identifiers across systems, and present unified dashboards while maintaining the validated state of source systems.
The Drug Supply Chain Security Act requires pharmaceutical manufacturers to serialize each package and case with unique identifiers, commission these identifiers in a database, capture aggregation relationships during packaging, and transmit transaction data to wholesalers and dispensers. This requires integrating serialization systems with packaging line equipment (labelers, vision systems, case packers), coordinating with contract packaging organizations, connecting to EPCIS repositories, and exchanging data with trading partner networks. Many manufacturers struggle with the integration complexity: packaging lines from different equipment vendors use different protocols, enterprise systems weren't designed for item-level tracking, and managing exception handling (line rejects, rework, returns) requires sophisticated business logic that commercial serialization platforms don't adequately address.
Pharmaceutical manufacturing under current Good Manufacturing Practices (cGMP) requires detailed documentation of every step in the production process. Traditional paper batch records create transcription errors, make deviations difficult to track, and slow down batch disposition decisions. Electronic batch record (EBR) systems replace paper with digital workflows, but implementation is complex: the software must enforce procedural controls (ensuring steps occur in the correct sequence), integrate with manufacturing equipment to capture process parameters, implement electronic signatures for critical steps, and handle exception scenarios like equipment failures or out-of-specification results. Many EBR implementations fail because they try to exactly replicate paper forms electronically rather than redesigning workflows to leverage digital capabilities, resulting in systems that are as cumbersome as paper without delivering efficiency gains.
Pharmaceutical quality management involves managing interconnected processes: deviations trigger investigations that may identify need for corrective actions, change controls require impact assessments across multiple departments, and CAPA effectiveness checks occur months after implementation. Many companies use general-purpose quality management software that doesn't understand pharmaceutical-specific workflows. These systems can't automatically determine which departments need to review a change control based on its category, don't enforce timelines aligned with regulatory requirements for deviation investigations, and can't generate the trending reports that quality teams need to identify systemic issues. The result is manual workarounds, spreadsheet tracking outside the QMS, and difficulty demonstrating control during regulatory inspections.
FDA guidance on data integrity (ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) creates specific technical requirements for pharmaceutical software systems. Every data entry must be timestamped with the exact time it was recorded, attributed to a specific user who was authenticated at that moment, and preserved in its original form even if later modified. Systems must prevent deletion of audit trail entries, ensure that all metadata travels with the data when transferred between systems, and implement controls preventing backdating of entries. Many commercial software packages weren't architected with these requirements in mind, storing audit data separately from transactional data or implementing audit trails that capture only limited information. Retrofitting data integrity controls into existing systems requires deep architectural changes that impact system performance and require revalidation.
New drug applications, annual reports, and regulatory responses require compiling data from clinical databases, manufacturing records, stability studies, and analytical method validations into electronic Common Technical Document (eCTD) format for submission to FDA, EMA, and other regulatory agencies. This process involves extracting data from multiple source systems, applying anonymization rules to clinical data, generating analysis datasets in CDISC SDTM and ADaM formats, validating data against submission specifications, and assembling thousands of documents into the hierarchical eCTD folder structure with proper metadata. Many pharmaceutical companies rely on manual processes with consultants spending months compiling submissions. The technical challenge is building automated pipelines that extract data from validated source systems, apply transformations while maintaining data lineage documentation, and generate submission-ready packages while ensuring that automation doesn't introduce risks to data integrity.
FreedomDev understood from day one that pharmaceutical software isn't just about technical functionality—it's about building systems that pass FDA scrutiny while actually improving our operations. Their LIMS implementation reduced our batch release cycle by nine days while eliminating the transcription errors that previously generated two or three OOS investigations monthly. During our last FDA inspection, the investigator specifically commented on the quality of our electronic records and audit trails.
We build laboratory information management systems specifically architected for pharmaceutical validation requirements with pre-built connectors for common analytical instruments. Our LIMS implementations include automated data capture from chromatography data systems, spectroscopy instruments, and dissolution testers, eliminating manual transcription. The system implements electronic signatures at critical review points, maintains complete audit trails showing original values and all subsequent changes, and generates certificate of analysis reports automatically when all testing is complete. One Midwest pharmaceutical manufacturer reduced batch release time by 40% by implementing our LIMS to replace a paper-based system, while simultaneously improving data integrity by eliminating transcription errors. The platform includes configurable stability study protocols, automatic alert generation when specifications are exceeded, and built-in statistical trending for method performance monitoring.
Our electronic batch record solutions transform paper-based manufacturing documentation into digital workflows that enforce procedural controls while improving efficiency. The system presents operators with electronic forms on hardened industrial touchscreens at each manufacturing step, automatically captures equipment parameters from programmable logic controllers (PLCs), and requires electronic signatures before allowing progression to subsequent steps. Batch record review time drops from days to hours because quality reviewers can sort directly to exception conditions rather than reviewing every page. We implement role-based access controls ensuring only qualified personnel can execute critical steps, automated calculations that eliminate arithmetic errors, and deviation workflows that automatically initiate when parameters exceed acceptance criteria. Similar to our [Real-Time Fleet Management Platform](/case-studies/great-lakes-fleet) that provides live operational visibility, our EBR systems give production managers real-time insight into batch status across multiple production lines.
We develop integration middleware that connects disparate clinical trial systems into unified dashboards for study coordinators and data managers. Our platform pulls data from EDC systems (Medidata Rave, Oracle InForm, REDCap), IRT systems managing randomization and drug supply, central laboratory LIMS, and ePRO applications, presenting consolidated views of patient enrollment, protocol deviations, data query status, and investigational product inventory. The system implements intelligent patient matching algorithms that reconcile identifiers across systems while maintaining blinding, automatically generates enrollment projections based on historical screening and randomization rates, and alerts study teams when drug supply levels drop below safety thresholds at specific sites. One clinical-stage biotech company reduced study startup time by three weeks by using our platform to automate site activation workflows that previously required coordinating across six different systems with manual data entry.
Our serialization platforms integrate with packaging line equipment to implement DSCSA compliance while providing operational visibility into product flow. We develop custom interfaces to serialization printers, vision inspection systems, and case aggregation equipment, capturing serial numbers at each packaging level and storing parent-child relationships in a centralized repository. The system automatically generates EPCIS transaction data when products ship, integrates with trading partner networks to exchange transaction information, and provides dashboards showing serialization performance metrics across multiple packaging lines. Exception handling workflows manage common scenarios: serialization equipment jams trigger automatic reprint requests, vision system rejects automatically remove serial numbers from the commissioned inventory, and rework procedures guide operators through decommissioning and recommissioning processes. We've implemented serialization solutions processing over 50 million serial numbers annually with 99.97% line availability.
We build pharmaceutical-specific quality management systems that automate routing, enforce regulatory timelines, and provide trending analytics. Our QMS implementations include configurable workflow engines that route deviations, change controls, and CAPAs based on product lines, manufacturing areas, and change categories. The system automatically determines which departments must review a packaging change control, enforces approval hierarchies ensuring senior quality reviewers approve high-risk changes, and tracks aging reports showing items approaching regulatory deadline requirements. Built-in trending dashboards aggregate data across quality events, identifying patterns like specific equipment associated with repeated deviations or process steps generating frequent change controls. One contract manufacturing organization reduced average deviation investigation time from 28 days to 14 days using our QMS, while simultaneously improving FDA inspection readiness with automatically generated metrics showing investigation completion rates.
Our [systems integration](/services/systems-integration) expertise connects pharmaceutical manufacturing systems with ERP platforms to provide unified operational visibility. We develop bidirectional integrations between manufacturing execution systems, quality management systems, LIMS, and ERP platforms like SAP, Oracle, and Microsoft Dynamics. These integrations automatically create batch records in the ERP when manufacturing orders are released, update inventory quantities when analytical testing completes, and post cost data from manufacturing execution systems to financial modules. Similar to our [QuickBooks Bi-Directional Sync](/case-studies/lakeshore-quickbooks) that maintained data consistency between operational and financial systems, our pharmaceutical integrations ensure master data (materials, specifications, routing) remains synchronized across platforms. The integration layer implements retry logic for failed transactions, maintains detailed logging for troubleshooting, and includes reconciliation dashboards that identify discrepancies requiring manual intervention.
We build data pipelines that automate regulatory submission generation, extracting data from clinical databases, document management systems, and manufacturing records to generate eCTD-formatted submissions. Our pipelines implement CDISC SDTM and ADaM transformation rules to convert clinical trial data into analysis datasets, apply anonymization procedures to protect patient confidentiality, validate datasets against FDA validator rules, and assemble documents into the hierarchical eCTD structure with appropriate metadata. The automation includes version control integration ensuring that submission packages can be reproduced exactly, data lineage tracking documenting transformation steps for regulatory transparency, and validation reports proving that automated processes produce consistent results. One specialty pharmaceutical company reduced annual report compilation time from six weeks to three days using our automated submission pipeline, while improving submission quality by eliminating manual transcription errors.
Our [custom software development](/services/custom-software-development) approach embeds data integrity controls into application architecture from initial design. We implement audit trail frameworks that capture not just data changes but the business context: why a change was made (reason for change field), what approval was required (electronic signature with meaning), and what the system state was at that moment (timestamp from validated time source). Database architectures use append-only ledgers for critical data, preventing deletion or overwriting of historical records. User interface designs make original values visible alongside current values, so reviewers can easily detect changes. Access controls implement role-based permissions at a granular level, preventing users from accessing functionality outside their job responsibilities. These architectural patterns align with FDA expectations for computerized system validation and data integrity, reducing the risk of regulatory findings during inspections.
Schedule a technical consultation with our senior architects.
Make your software work for you. Let's build a sensible solution for Pharmaceutical.
